Oxford BioTherapeutics, an Oxon, UK-based clinical stage biotechnology company, received a $10m term loan from Silicon Valley Bank.
The debt will complement new equity the company is raising and the total financing of equity and debt will allow the company to accelerate the expansion of its research and development efforts.
Led by Christian Rohlff, CEO, Oxford BioTherapeutics is an international clinical stage biotechnology company focused on developing innovative antibody based therapeutics, including antibody-drug conjugates (ADCs), to treat cancer and other diseases. It uses the optimal combination of technologies in ADC development through its collaborations with companies in the field and its novel OGAP® target discovery system to provide a range of validated, novel antigen targets.
FinSMEs
30/07/2015